Compare
Butterfly Network, Inc. vs NeuroPace Inc vs Kestra Medical Technologies, Ltd. vs Beta Bionics, Inc.
| Latest fiscal year | Butterfly Network, Inc. BFLY | NeuroPace Inc NPCE | Kestra Medical Technologies, Ltd. KMTS | Beta Bionics, Inc. BBNX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-04-30 | 2025-12-31 |
| Revenue | $97.61M | $99.99M | $95.13M | $100.25M |
| Revenue growth (YoY) | +19.0% | +25.1% | +59.0% | +53.9% |
| Gross margin | 46.9% | 77.2% | 51.4% | 55.4% |
| Operating margin | -88.5% | -16.3% | -141.6% | -71.5% |
| Net margin | -79.0% | -21.5% | -138.4% | -73.0% |
| Net income | -$77.06M | -$21.46M | -$131.61M | -$73.20M |
| EPS (Diluted) | -$0.31 | -$0.66 | -$2.43 | -$1.81 |
| Operating cash flow | -$12.70M | -$11.01M | -$81.70M | -$50.92M |
| Free cash flow | -$16.05M | -$11.34M | -$116.59M | -$56.22M |
| Cash & equivalents | $150.49M | $21.69M | $99.71M | $31.58M |
| Total assets | $296.53M | $105.56M | $358.46M | $328.74M |
| Total liabilities | $100.55M | $86.53M | $98.81M | $41.13M |
| Shareholders' equity | $195.98M | $19.03M | $259.66M | $287.61M |
| Return on year-end equity | -39.3% | -112.8% | -50.7% | -25.5% |
| Shares outstanding | n/a | 33.57M | 58.38M | 44.36M |
Revenue, most recent five fiscal years
| Fiscal year | Butterfly Network, Inc. | NeuroPace Inc | Kestra Medical Technologies, Ltd. | Beta Bionics, Inc. |
|---|---|---|---|---|
| Latest | $97.61M Ended 2025-12-31 | $99.99M Ended 2025-12-31 | $95.13M Ended 2026-04-30 | $100.25M Ended 2025-12-31 |
| 1 year earlier | $82.06M Ended 2024-12-31 | $79.91M Ended 2024-12-31 | $59.81M Ended 2025-04-30 | $65.12M Ended 2024-12-31 |
| 2 years earlier | $65.90M Ended 2023-12-31 | $65.42M Ended 2023-12-31 | $27.81M Ended 2024-04-30 | $11.99M Ended 2023-12-31 |
| 3 years earlier | $73.39M Ended 2022-12-31 | $45.52M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $62.56M Ended 2021-12-31 | $45.18M Ended 2021-12-31 | n/a | n/a |